New Ebola virus research boosts pandemic preparedness
Promising antibody may prove useful against deadly outbreaks
Disease Ebola
LJI discovery paves the way for antivirals against Ebola virus and its deadly relatives
Scientists capture first look at key viral structure within infected host cells
Saphire Lab
Erica Ollmann Saphire, Ph.D., MBA, studies, at the molecular level, how and why viruses are pathogenic. This work provides the roadmap for medical defense.
LJI scientists win ‘Prebys Research Heroes’ funding
Prebys Foundation celebrates ground-breaking female researchers
Erica Ollmann Saphire wins 2023 Pantheon Award from California Life Sciences
LJI President and CEO celebrated among California’s leading life sciences innovators
A new look inside Ebola’s ‘viral factories’
LJI researchers reveal a hidden side of how Ebola virus replicates inside host cells
LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection
New findings emphasize the benefits of antibody cocktails over monotherapy approaches
The sky, the sea, and Ebola virus
Jingru Fang shares how her Ph.D. research inspired a vivid painting
Targeting a human protein may stop Ebola virus in its tracks
To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.
Promising antibody cocktail takes on Ebola virus—and its deadly cousin
LJI team uncovers how one odd antibody does some heavy lifting
Learning from men. Learning from women.
Men and women have different immune systems. With a better understanding of sex-specific immune differences, scientists can more effectively fight infections, cancers, heart disease, and even pregnancy complications.
Shape-shifting Ebola virus protein exploits human RNA to change shape
New study highlights VP40 as a promising therapeutic target
La Jolla Institute for Immunology acquires Berkeley Lights Beacon® platform
The Beacon optofluidic technology will be used to speed the identification of lifesaving treatments for deadly viruses including Ebola, Lassa and others.
La Jolla Institute-led consortium awarded up to $35 million by NIH
The grant establishes the global Viral Immunotherapeutic Consortium to develop new treatments for Ebola, Lassa and other viral threats
